Dr. Jeffrey L. Cummings In The News
Medscape
GLP-1s have been a breakthrough for obesity and diabetes. A 2022 study examined data from trials of GLP-1s in nearly 16,000 patients with diabetes, and showed that the drugs were associated with a 53% reduction in dementia risk.
Chemical & Engineering News
As current drugs fall short, companies are exploring new targets to treat the neurodegenerative disease
Nature Medicine
For decades, diagnosing Alzheimer’s disease (AD) has required access to specialist memory clinics, neuroimaging or invasive cerebrospinal fluid (CSF) testing. That paradigm is starting to shift. In 2025, the US Food and Drug Administration (FDA) cleared the first blood-based biomarker tests intended to aid the assessment of AD.
Globe Newswire
Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias. This is a transformative, international study, but CNS is the only Las Vegas research site participating.